Diminished Treg neuroprotection, T cell activation, Th-1 polarization, increased CD71+ and CD40L expression and IL-16 production are new drug targets to treat the T effector-associated neurotoxicity of the acute phase of severe MDD. This evidence concerns the gene IL16 and major depressive disorder.